Business Award - November 23, 2021
EIT Health and Biogen launch Neurotech Prize
The purpose of the new programme is to rapidly identify technological solutions to the growing challenge of Alzheimer’s disease. Teams and researchers can apply now to be considered to take part, states EIT Health. Participants will work with experts to receive mentoring and funding to bring their ideas to patients and their families in the […]
Global report - January 25, 2021
Biogen to develop digital biomarkers of cognitive health
Biogen has announced a new virtual research study, in collaboration with Apple, to investigate the role Apple Watch and iPhone could play in monitoring cognitive performance and screening for decline in cognitive health including mild cognitive impairment (MCI). The multi-year, observational research study will be launched later in 2021 and will enroll participants including young […]
Drug Development Pharma - May 13, 2016
Sobi’s Alprolix approved in the EU
Swedish Orphan Biovitrum and Biogen has announced that the European Commission (EC) has approved Alprolix (rFIXFc), their extended half-life therapy, for the treatment of haemophilia B in all 28 European Union (EU) member states and maintained its orphan designation. Alprolix is the only recombinant factor IX Fc Fusion protein therapy for haemophilia B to offer people […]
Collaboration - June 5, 2015
Biogen Files MAA for Hemophilia Drug
Swedish Orphan Biovitrum AB (Sobi’s) partner Biogen has submitted a Marketing Authorisation Application (MAA) for Alprolix (rFIXFc) to the European Medicines Agency (EMA). Sobi has an opt-in right to assume final development and commercialization of Alprolix in Europe, Russia, certain countries in the Middle East, and North Africa, according to Sobi. The MAA filing with […]
